Literature DB >> 27844165

Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.

Joachim Havla1, T Kümpfel2, R Schinner3, M Spadaro2, E Schuh2, E Meinl2, R Hohlfeld2,4, O Outteryck2,5.   

Abstract

Antibodies against conformation-dependent epitopes of myelin-oligodendrocyte-glycoprotein (MOG-abs) are present in subgroups of neuromyelitis optica spectrum disorder (NMOSD), recurrent optic neuritis (rON), multiple sclerosis (MS), and anti-NMDAR encephalitis. Using optical coherence tomography (OCT) we assessed whether MOG-abs might serve as potential marker of retinal axonal degeneration. We investigated a clinically heterogeneous cohort of 13 MOG-abs-positive patients (4 MOG-abs-positive rON, 4 MOG-abs-positive adult MS, 3 MOG-abs-positive relapsing encephalomyelitis, 2 MOG-abs-positive aquaporin-4-abs-negative NMOSD). As controls, we studied 13 age, sex and ON episode(s)-matched MOG-abs and aquaporin-4-abs-negative (AQP4-abs-negative) MS patients and 13 healthy controls (HC). In addition, we investigated 19 unmatched AQP4-abs-positive MOG-abs-negative NMOSD subjects. Considering all eyes, global pRNFL [in µm, mean (SD)] was significantly reduced in MOG-abs-positive patients [72.56 (22.71)] compared to MOG-abs-negative MS [80.81 (13.55), p = 0.0128], HCs [103.54 (8.529), p = 0.0014] and NMOSD [88.32 (18.43), p = 0.0353]. Non ON eyes from MOG-abs-positive subjects showed significant subclinical atrophy of temporal pRNFL quadrants. Microcystic macular edema (MME) was observed only in eyes of MOG-abs-positive (24%) and AQP4-abs-positive NMOSD (5.6%), but not in MOG-abs-negative MS or HC (p < 0.01). MOG-abs may serve as potential marker of retinal degeneration. Specifically, MOG-abs-related OCT features predominate in temporal pRNFL quadrants (resembling the MS retinal pattern), might be more severe than AQP4-abs-positive NMOSD, indicate subclinical pathology, and may be associated with MME.

Entities:  

Keywords:  Microcystic macular edema; Multiple sclerosis; Myelin-oligodendrocyte-glycoprotein; Neuromyelitis optica spectrum disorder; Optical coherence tomography

Mesh:

Substances:

Year:  2016        PMID: 27844165     DOI: 10.1007/s00415-016-8333-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  40 in total

1.  A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis.

Authors:  Olivier Outteryck; Bilal Majed; Sabine Defoort-Dhellemmes; Patrick Vermersch; Hélène Zéphir
Journal:  Mult Scler       Date:  2015-03-31       Impact factor: 6.312

2.  Microcystic macular oedema confirmed, but not specific for multiple sclerosis.

Authors:  Lisanne J Balk; Joep Killestein; Chris H Polman; Bernard M J Uitdehaag; Axel Petzold
Journal:  Brain       Date:  2012-10-17       Impact factor: 13.501

3.  The clinical spectrum of microcystic macular edema.

Authors:  Marloes C Burggraaff; Jennifer Trieu; Willemien A E J de Vries-Knoppert; Lisanne Balk; Axel Petzold
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-18       Impact factor: 4.799

4.  Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.

Authors:  Sudarshini Ramanathan; Kristina Prelog; Elizabeth H Barnes; Esther M Tantsis; Stephen W Reddel; Andrew P D Henderson; Steve Vucic; Mark P Gorman; Leslie A Benson; Gulay Alper; Catherine J Riney; Michael Barnett; John D E Parratt; Todd A Hardy; Richard J Leventer; Vera Merheb; Margherita Nosadini; Victor S C Fung; Fabienne Brilot; Russell C Dale
Journal:  Mult Scler       Date:  2015-07-10       Impact factor: 6.312

5.  Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study.

Authors:  Shiv Saidha; Elias S Sotirchos; Mohamed A Ibrahim; Ciprian M Crainiceanu; Jeffrey M Gelfand; Yasir J Sepah; John N Ratchford; Jiwon Oh; Michaela A Seigo; Scott D Newsome; Laura J Balcer; Elliot M Frohman; Ari J Green; Quan D Nguyen; Peter A Calabresi
Journal:  Lancet Neurol       Date:  2012-10-04       Impact factor: 44.182

6.  Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.

Authors:  Joanna Kitley; Patrick Waters; Mark Woodhall; M Isabel Leite; Andrew Murchison; Jithin George; Wilhelm Küker; Saleel Chandratre; Angela Vincent; Jacqueline Palace
Journal:  JAMA Neurol       Date:  2014-03       Impact factor: 18.302

7.  Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.

Authors:  Maria Sepúlveda; Thaís Armangue; Eugenia Martinez-Hernandez; Georgina Arrambide; Nuria Sola-Valls; Lidia Sabater; Nieves Téllez; Luciana Midaglia; Helena Ariño; Patrick Peschl; Markus Reindl; Alex Rovira; Xavier Montalban; Yolanda Blanco; Josep Dalmau; Francesc Graus; Albert Saiz
Journal:  J Neurol       Date:  2016-05-04       Impact factor: 4.849

8.  Microcystic macular edema: retrograde maculopathy caused by optic neuropathy.

Authors:  Mathias Abegg; Muriel Dysli; Sebastian Wolf; Jens Kowal; Pascal Dufour; Martin Zinkernagel
Journal:  Ophthalmology       Date:  2013-10-15       Impact factor: 12.079

Review 9.  Vision and vision-related outcome measures in multiple sclerosis.

Authors:  Laura J Balcer; David H Miller; Stephen C Reingold; Jeffrey A Cohen
Journal:  Brain       Date:  2014-11-28       Impact factor: 13.501

10.  Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.

Authors:  Marie C Mayer; Constanze Breithaupt; Markus Reindl; Kathrin Schanda; Kevin Rostásy; Thomas Berger; Russell C Dale; Fabienne Brilot; Tomas Olsson; Dieter Jenne; Anne-Katrin Pröbstel; Klaus Dornmair; Hartmut Wekerle; Reinhard Hohlfeld; Brenda Banwell; Amit Bar-Or; Edgar Meinl
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

View more
  22 in total

1.  MOG antibody-related disorders: common features and uncommon presentations.

Authors:  Álvaro Cobo-Calvo; Anne Ruiz; Hyacintha D'Indy; Anne-Lise Poulat; Maryline Carneiro; Nicolas Philippe; Françoise Durand-Dubief; Kumaran Deiva; Sandra Vukusic; Vincent Desportes; Romain Marignier
Journal:  J Neurol       Date:  2017-08-02       Impact factor: 4.849

2.  Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning.

Authors:  Elias S Sotirchos; Angeliki Filippatou; Kathryn C Fitzgerald; Sara Salama; Santiago Pardo; Jiangxia Wang; Esther Ogbuokiri; Norah J Cowley; Nicole Pellegrini; Olwen C Murphy; Maureen A Mealy; Jerry L Prince; Michael Levy; Peter A Calabresi; Shiv Saidha
Journal:  Mult Scler       Date:  2019-07-31       Impact factor: 6.312

Review 3.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

4.  Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).

Authors:  Jonathan A Gernert; Rebecca Wicklein; Benjamin Knier; Joachim Havla; Bernhard Hemmer; Tania Kümpfel
Journal:  J Neurol       Date:  2022-10-16       Impact factor: 6.682

Review 5.  [Optical coherence tomography in neuromyelitis optica spectrum disorders].

Authors:  F C Oertel; H Zimmermann; A U Brandt; F Paul
Journal:  Nervenarzt       Date:  2017-12       Impact factor: 1.214

6.  Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China.

Authors:  Guixian Zhao; Qian Chen; Yongheng Huang; Zhenxin Li; Xinghuai Sun; Ping Lu; S Yan; Min Wang; Guohong Tian
Journal:  J Neurol       Date:  2017-11-03       Impact factor: 4.849

Review 7.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease.

Authors:  Markus Reindl; Patrick Waters
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

Review 8.  Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment.

Authors:  Sidney M Gospe; John J Chen; M Tariq Bhatti
Journal:  Eye (Lond)       Date:  2020-12-15       Impact factor: 3.775

Review 9.  Defining distinct features of anti-MOG antibody associated central nervous system demyelination.

Authors:  Martin S Weber; Tobias Derfuss; Imke Metz; Wolfgang Brück
Journal:  Ther Adv Neurol Disord       Date:  2018-03-29       Impact factor: 6.570

10.  Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?

Authors:  Joachim Havla; Thivya Pakeerathan; Kevin Rostasy; Ilya Ayzenberg; Carolin Schwake; Jeffrey L Bennett; Ingo Kleiter; Ana Felipe-Rucián; Stephanie C Joachim; Amelie S Lotz-Havla; Tania Kümpfel; Markus Krumbholz; Eva M Wendel; Markus Reindl; Charlotte Thiels; Thomas Lücke; Kerstin Hellwig; Ralf Gold
Journal:  J Neuroinflammation       Date:  2021-05-29       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.